If EPS Growth Is Important To You, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Presents An Opportunity

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.

In contrast to all that, many investors prefer to focus on companies like Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049), which has not only revenues, but also profits. Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

How Fast Is Jilin Province Huinan Changlong Bio-pharmacy Growing?

The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Jilin Province Huinan Changlong Bio-pharmacy managed to grow EPS by 8.7% per year, over three years. That's a pretty good rate, if the company can sustain it.

One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. While we note Jilin Province Huinan Changlong Bio-pharmacy achieved similar EBIT margins to last year, revenue grew by a solid 4.7% to CN¥881m. That's progress.

In the chart below, you can see how the company has grown earnings and revenue, over time. To see the actual numbers, click on the chart.

Check out our latest analysis for Jilin Province Huinan Changlong Bio-pharmacy

Jilin Province Huinan Changlong Bio-pharmacy isn't a huge company, given its market capitalisation of HK$1.2b. That makes it extra important to check on its balance sheet strength.

Are Jilin Province Huinan Changlong Bio-pharmacy Insiders Aligned With All Shareholders?

It's pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. Shareholders will be pleased by the fact that insiders own Jilin Province Huinan Changlong Bio-pharmacy shares worth a considerable sum. With a whopping CN¥411m worth of shares as a group, insiders have plenty riding on the company's success. At 35% of the company, the co-investment by insiders fosters confidence that management will make long-term focussed decisions.

While it's always good to see some strong conviction in the company from insiders through heavy investment, it's also important for shareholders to ask if management compensation policies are reasonable. A brief analysis of the CEO compensation suggests they are. The median total compensation for CEOs of companies similar in size to Jilin Province Huinan Changlong Bio-pharmacy, with market caps between CN¥720m and CN¥2.9b, is around CN¥2.5m.

The Jilin Province Huinan Changlong Bio-pharmacy CEO received total compensation of just CN¥776k in the year to December 2024. That looks like a modest pay packet, and may hint at a certain respect for the interests of shareholders. CEO compensation is hardly the most important aspect of a company to consider, but when it's reasonable, that gives a little more confidence that leadership are looking out for shareholder interests. It can also be a sign of good governance, more generally.

Should You Add Jilin Province Huinan Changlong Bio-pharmacy To Your Watchlist?

As previously touched on, Jilin Province Huinan Changlong Bio-pharmacy is a growing business, which is encouraging. The growth of EPS may be the eye-catching headline for Jilin Province Huinan Changlong Bio-pharmacy, but there's more to bring joy for shareholders. With company insiders aligning themselves considerably with the company's success and modest CEO compensation, there's no arguments that this is a stock worth looking into. Before you take the next step you should know about the 1 warning sign for Jilin Province Huinan Changlong Bio-pharmacy that we have uncovered.

Although Jilin Province Huinan Changlong Bio-pharmacy certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of Hong Kong companies that not only boast of strong growth but have strong insider backing.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.